Hi Tom, I am not sold yet on the relevance of heteroresistance on clinical outcomes although definitely up for debate. On this post hoc analysis of a randomised population they didnt see a difference for example journals-asm-org.libproxy.ucl.ac.uk/doi/epub/10.....
January 18, 2025 at 12:33 PM
Hi Tom, I am not sold yet on the relevance of heteroresistance on clinical outcomes although definitely up for debate. On this post hoc analysis of a randomised population they didnt see a difference for example journals-asm-org.libproxy.ucl.ac.uk/doi/epub/10.....
Our approach is definitely not perfect but ensures a patient actually received an ineffective antimicrobial during a resistant infection (instrinsic or not), which was considered to have contributed to their death by two different people. I think this is a fair starting point at the patient level.
January 9, 2025 at 3:20 PM
Our approach is definitely not perfect but ensures a patient actually received an ineffective antimicrobial during a resistant infection (instrinsic or not), which was considered to have contributed to their death by two different people. I think this is a fair starting point at the patient level.
I like the methodology of the Tb paper - it would be challenging to extrapolate to Gram-negative AMR of acute infections.
January 9, 2025 at 3:19 PM
I like the methodology of the Tb paper - it would be challenging to extrapolate to Gram-negative AMR of acute infections.
Hi @tomayates.bsky.social, agree that attribution is challenging. Counterfactuals are attractive but imo impossible to use meaningfully at the patient level. They also come with a lot of caveats when used in epidemiological studies (e.g. presise CFRs in GRAM study).
January 9, 2025 at 3:14 PM
Hi @tomayates.bsky.social, agree that attribution is challenging. Counterfactuals are attractive but imo impossible to use meaningfully at the patient level. They also come with a lot of caveats when used in epidemiological studies (e.g. presise CFRs in GRAM study).